Lupin Performance
- Today's Low
- ₹2,256
- Today's High
- ₹2,301
- 52 Week Low
- ₹1,837
- 52 Week High
- ₹2,494
- Open Price₹2,289
- Previous Close₹2,276
- Volume2,937,904
- 50 DMA₹2,289.49
- 100 DMA₹2,247.91
- 200 DMA₹2,172.23
Lupin Chart
Investment Returns
- Over 1 Month -1.89%
- Over 3 Month -1.49%
- Over 6 Month + 8.91%
- Over 1 Year + 15.11%
Smart Investing Starts Here Start SIP with Lupin for Steady Growth!
Lupin Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 19.4
- PEG Ratio
- 0.3
- Market Cap Cr
- 103,683
- P/B Ratio
- 5
- Average True Range
- 52.85
- EPS
- 126.13
- Dividend Yield
- 0.5
- MACD Signal
- -9.43
- RSI
- 45.61
- MFI
- 46.2
Latest Stock News Updates
Pharmaceuticals company Lupin announced Q4FY26 & FY26 results Consolidated Financial Highlights: The company’s sales for Q4FY26 stood at Rs 73,919 million, representing a YoY growth of 32.9% from Rs 55,622 million and a QoQ growth of 4.1% from Rs 71,005 million. Total Revenue from operations for the quarter was Rs 74,747 million, up 31.9% YoY from Rs 56,671 million and up 4.3% QoQ from Rs 71,675 million. EBITDA for Q4FY26 was Rs 26,263 million, marking a significant YoY increase of 90.6% compared to Rs 13,781 million and a QoQ rise of 10.5% from Rs 23,766 million. Profit Before Tax (PBT) for the quarter reached Rs 19,280 million, reflecting a YoY growth of 115.2% from Rs 8,958 million and a QoQ growth of 26.7% from Rs 15,220 million. Net profit (PAT) for Q4FY26 stood at Rs 14,687 million, an increase of 87.7% YoY from Rs 7,824 million and a 24.4% increase QoQ from Rs 11,805 million. For the full year FY26, Sales reached Rs 2,74,875 million, representing a 23.9% YoY growth from Rs 2,21,921 million in FY25. Annual EBITDA for FY26 was Rs 92,405 million, up 68.6% YoY from Rs 54,792 million in FY25. Full year Profit Before Tax (PBT) stood at Rs 68,726 million, a growth of 71.2% YoY compared to Rs 40,150 million. Net profit (PAT) for the full year FY26 was Rs 53,555 million, marking a 62.0% YoY increase from Rs 33,063 million in FY25. Business Highlights: Dividend Recommendation: The Board has recommended a dividend of 900% based on the long-term outlook. Segment Performance (U.S.): Sales for FY26 were Rs 1,16,783 million (USD 1,318 million), up 46.0% YoY, accounting for 42% of global sales. In Q4FY26, U.S. sales were Rs 33,987 million (USD 371 million), a 56.9% increase YoY. Segment Performance (India): India sales for FY26 stood at Rs 81,140 million, up 7.1% YoY, contributing 30% to global sales. Quarter sales for India in Q4FY26 were Rs 19,082 million, up 11.5% YoY. Segment Performance (Emerging Markets): Sales for FY26 reached Rs 34,828 million, up 35.2% YoY. For Q4FY26, sales in this segment were Rs 9,906 million, a YoY growth of 49.2%. Segment Performance (Other Developed Markets): Annual sales for FY26 were Rs 32,439 million, up 13.3% YoY. Quarter sales for Q4FY26 were Rs 8,453 million, up 7.1% YoY. Segment Performance (Global API): Global API sales for FY26 were Rs 9,685 million, a decline of 17.7% YoY. However, Q4FY26 sales for the segment grew 7.6% YoY to reach Rs 2,491 million. Formulations: Total formulations sales for FY26 reached Rs 2,65,190 million, reflecting a YoY growth of 26.2%. Research and Development: Investment in R&D; was Rs 20,631 million (7.5% of sales) for FY26, compared to Rs 17,968 million in FY25. For Q4FY26, R&D; investment was Rs 5,898 million (8.0% of sales). Net Debt: As of March 31, 2026, Net Debt stands at Rs -46,358 million. Nilesh Gupta, Managing Director, Lupin, said: “Our fourth quarter and full-year results underscore the strength and resilience of our business across key geographies, with the U.S. and India delivering strong sales growth and margin expansion. Building on this momentum, we are well-positioned to accelerate performance through strategic investments in technology, disciplined execution, and operational efficiencies, driving sustainable and profitable growth”. Result PDF
- Trendlyne
- 3 weeks ago
The company had posted a consolidated profit after tax (PAT) of 782.4 crore in the corresponding quarter of the preceding fiscal, Lupin Ltd said in a regulatory filing
- Business Line
- 3 weeks 1 day ago
The tablets, available in multiple strengths, are bioequivalent to Xigduo XR, a widely used anti-diabetic medication
- Business Line
- 1 month 1 week ago
Lupin Financials
Lupin Technicals
EMA & SMA
- Bearish Moving Average 11
- Bullish Moving Average 5
- 20 Day
- ₹2,289.37
- 50 Day
- ₹2,289.49
- 100 Day
- ₹2,247.91
- 200 Day
- ₹2,172.23
Resistance and Support
- R3 2,339.20
- R2 2,320.30
- R1 2,294.00
- S1 2,248.80
- S2 2,229.90
- S3 2,203.60
Lupin Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-05-07 | Audited Results & Final Dividend | |
| 2026-02-12 | Quarterly Results | |
| 2025-11-06 | Quarterly Results & Others | To consider other business matters. per share(325%)Final Dividend |
| 2025-08-05 | Quarterly Results & Others | To consider other business matters. per share(325%)Final Dividend |
| 2025-05-14 | Audited Results & Final Dividend |
Lupin F&O
About Lupin
Dr Desh Bandhu Gupta founded in 1968 in Mumbai, Lupin is one of the top pharmaceutical manufacturers. It has 15 manufacturing facilities, 6 API facilities, 7 research facilities and more than 23 global offices.
Lupin ranks 6th by sales in India. It ranks #2 in respiratory and #3 in cardiac and anti-diabetes segments. While the market growth in the chronic disease portfolio has been 11% in the last five years, Lupin has been growing at 14% YoY.
Over the last 4 years, it has invested over $1bn in R&D in areas of biosimilars, complex generics, long-acting complex injectables, inhalation and speciality portfolio.
Business Verticals
1. Global Formulations
2. Active Pharmaceuticals Ingredients (API)
3. Biotech
4. Specialty Business
5. Over The Counter (OTC)
6. Biosimilars
7. Generic drugs
Company History
Lupin commenced operations in 1968 on Gudi Padwa as a vitamins manufacturer. It is named after the Lupin flower, which can tolerate infertile soils and poor climatic conditions. Its first major order was iron and folic acid tablets for mother and child healthcare programmes backed by the Government of India.
Today, it develops branded and generic formulations, APIs, and biotechnology products and sells across 100 markets, including the US, Japan, and Mexico. Lupin is one of the world's largest manufacturers of TB drugs. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, Anti-Infective, and Non-Steroidal Anti-Inflammatory Drugs.
Milestones
1968 - Dr Desh Bandhu Gupta started Lupin.
1972 - Lupin Laboratories Pvt. Ltd. was incorporated.
1979 - They commissioned the first formulation plant and R&D Centre at Aurangabad.
1981 - They started the production of Ethambutol.
1987 - Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar went on stream.
1988 - Commenced Lupin Human Welfare and Research Foundation (LHWRF).
1989 - Started Lupin Chemicals (Thailand) Ltd. Received U.S. FDA approvals for the Ankleshwar and Mandideep plants.
1991 - Initiated the production of injectable Cephalosporin at Mandideep.
1992 - Commenced a sterile fermentation plant for injectable Cephalosporins at Mandideep.
1993 - Lupin Laboratories Ltd. and Lupin Chemicals Ltd. floated their IPOs.
1997 - Three facilities received U.S. FDA approvals.
2000 - Another plant received US FDA approval.
2001 - Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd. to form Lupin Ltd. and established the Lupin Research Park in Pune. Lupin became the only Asian pharmaceutical company to receive U.S. FDA approvals for its sterile Cephalosporin facility.
2002 - ORG-Marg rated Rablet as the 2nd best launch of 2002-03; patent filings exceed 100.
2003 - Received WHO approval for the formulation plant at Aurangabad. Lupin Pharmaceuticals Inc. USA is formed.
2004 - Started U.S. brands’ business with the launch of Suprax.
2005 - Commenced its generics business in the U.S. Implemented ESOP.
2006 - Announced the issue of FCCBs, with a listing on the Singapore Stock Exchange.
2007 - Acquired Kyowa Pharmaceuticals of Japan; and Rubamin Laboratories of India.
2008 - Acquired Hormosan Pharma GmbH, Germany. Also acquired stakes in Generic. Health Pty Ltd., Australia and Pharma Dynamics, South Africa.
2009 - Acquired majority stake in Multi-Care Pharmaceuticals Inc., Philippines.
2010 - Lupin ranked the 5th largest generic player in the U.S.
2011 - Began commercial production at the new oral solid dosage facility at Pithampur; acquired I’rom Pharmaceuticals, Japan and of worldwide rights for the Goanna Brand.
2012 - Lupin enters Nifty 50.
2014 - Acquired Nanomi BV of the Netherlands and Laboratorios Grin S.A. De C.V., Mexico.
2015 - Acquired Pharma Dynamics, South Africa, Medquimica Industria, Brazil; Specialty product portfolio of Temmler Pharma GMBH & Co., Germany.
2016 - Acquired Gavis Pharma, U.S; launched a new plant at Tottori, Japan.
2017 - Launched Softovac in the OTC segment; acquired Symbiomix Therapeutics, U.S.
2019 - Divestment of Kyowa Pharmaceutical Industry Co. Ltd in Osaka.
2020 - Launched Etanercept Biosimilar in EU and gProAir, a key inhalation product.
View More- NSE Symbol
- LUPIN
- BSE Symbol
- 500257
- Managing Director
- Mr. Nilesh D Gupta
- ISIN
- INE326A01037
Similar Stocks to Lupin
Popular Stocks
Lupin FAQs
Lupin share price is ₹2,267 As on 30 May, 2026 | 08:33
The Market Cap of Lupin is ₹103682.8 Cr As on 30 May, 2026 | 08:33
The P/E ratio of Lupin is 19.4 As on 30 May, 2026 | 08:33
The PB ratio of Lupin is 5 As on 30 May, 2026 | 08:33
For the year ending March 2022, Lupin reported a consolidated sales figure of INR 16,405 crores and a net loss of INR 1,528 crores. Its standalone sales and net loss for the same period stood at INR 11,772 crores and 189 crores respectively.
Lupin’s future looks slightly bleak. The company has shown a negative net profit growth rate of 2.18% and revenue growth of 3.10% for the past 3 years. However, the company is virtually debt-free.
You can easily buy and sell the company's shares by creating a Demat account with 5Paisa.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.